We are live on ! Find out more
PTCT icon

PTC Therapeutics

132 hedge funds and large institutions have $1.47B invested in PTC Therapeutics in 2014 Q4 according to their latest regulatory filings, with 38 funds opening new positions, 58 increasing their positions, 23 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

660% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 5

152% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 23

50% more funds holding in top 10

Funds holding in top 10: 23 (+1)

37% more capital invested

Capital invested by funds: $1.07B → $1.47B (+$395M)

33% more funds holding

Funds holding: 99132 (+33)

53% less call options, than puts

Call options by funds: $1.5M | Put options by funds: $3.18M

Holders
132
Holders Change
+33
Holders Change %
+33.33%
% of All Funds
3.52%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.08%
New
38
Increased
58
Reduced
23
Closed
5
Calls
$1.5M
Puts
$3.18M
Net Calls
-$1.68M
Net Calls Change
-$1.68M

PTCT Hedge Fund Activity: Q4 2014 in Review

132 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2014, worth a combined $1.47B — up 37% from $1.07B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new PTCT positions and 5 closed out — a net gain of 33 holders — while 58 added to existing stakes and 23 trimmed.

The largest buyer was BB Biotech, opening a new position worth an estimated $54.1M. The largest seller was Bain Capital Public Equity Management, cutting an estimated $34.3M.

  • 132 institutional investors held PTC Therapeutics (PTCT) as of Q4 2014, up from 99 in Q3 2014.
  • Funds reported $1.47B of PTC Therapeutics stock for Q4 2014, up 37% quarter-over-quarter.
  • 38 funds opened new PTC Therapeutics positions in Q4 2014 and 5 closed out, a net change of +33 holders.
  • The largest PTC Therapeutics buyer in Q4 2014 was BB Biotech, an estimated $54.1M added.
  • The largest PTC Therapeutics seller in Q4 2014 was Bain Capital Public Equity Management, an estimated $34.3M sold.

Based on aggregated 13F filings for Q4 2014.